Provided by Tiger Trade Technology Pte. Ltd.

AbbVie

264.96
+3.131.20%
Post-market: 266.401.44+0.54%19:59 EDT
Volume:5.16M
Turnover:1.37B
Market Cap:468.29B
PE:74.85
High:266.84
Open:260.70
Low:260.10
Close:261.83
52wk High:267.47
52wk Low:190.75
Shares:1.77B
Float Shares:1.76B
Volume Ratio:1.05
T/O Rate:0.29%
Dividend:6.83
Dividend Rate:2.58%
EPS(TTM):3.54
EPS(LYR):2.36
ROE:6225.00%
ROA:10.51%
PB:-78.90
PE(LYR):112.27

Loading ...

U.s. Research Roundup-danaher, Gm, Msci

Reuters
·
Jul 22

Therapeuticsmd Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Jul 21

AbbVie’s ABBV-8736 Injection Study Signals Quiet But Meaningful Pipeline Progress

TIPRANKS
·
Jul 21

European Equities Mixed in Friday Trading; ASML to Give Staff One-Time Bonus

MT Newswires Live
·
Jul 17

AbbVie (ABBV) Boey Approval Puts Its Growth Story And Valuation Back In Focus

Simply Wall St.
·
Jul 17

Abbvie’s Allergan Aesthetics Wins EU Approval for Boey Frown-line Treatment

Reuters
·
Jul 17

Abbvie - European Commission Approves Boey for Temporary Improvement of Glabellar Lines in Adults

THOMSON REUTERS
·
Jul 17

Regenxbio Tumbles on Deep-discounted $100 Mln Equity Offering

Reuters
·
Jul 17

7 Stocks that actually play defence: Jon Erlichman

Bloomberg
·
Jul 17

Why Healthcare Stocks Look Like a Haven in This Market

Dow Jones
·
Jul 17

Why Abbott Stock is Having Its Best Day in 24 Years

Dow Jones
·
Jul 16

AbbVie Inc Stock (ABBV) Moved Up by 3.32% on Jul 16: What Signal Does It Send?

TradingKey
·
Jul 16

Movement Alert|AbbVie Rises 3.01% in Regular Trading, Multiple Investment Banks Raise Price Targets

Market Focus
·
Jul 16

Arcutis Appoints Mirum CEO Chris Peetz to Board

Reuters
·
Jul 16

Therapeuticsmd Inc. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Jul 16

Rxsight Names Aziz Mottiwala CEO, Ron Kurtz to Become Chief Medical Officer

Reuters
·
Jul 16

Analysts Are Bullish on Top Healthcare Stocks: Fractyl Health, Inc. (GUTS), AbbVie (ABBV)

TIPRANKS
·
Jul 16

AbbVie’s Bimatoprost SR Extension Data: Why Long-Term Glaucoma Safety Matters for Investors

TIPRANKS
·
Jul 16

Abbvie is Maintained at Neutral by Citigroup

Dow Jones
·
Jul 15

Citigroup Adjusts Price Target on AbbVie to $260 From $230, Maintains Neutral Rating

MT Newswires Live
·
Jul 15